Fundraising Fox
/Companies
Sign in

Sofregen

Cambridge, US · Founded 2014 · 8 employees on LinkedIn · 2 known investors

Find your way into Sofregen

Sign up to see every warm intro you have to Sofregen

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Sofregen team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Sofregen develops silk protein-based biomaterials and medical devices for soft tissue regeneration in aesthetic and surgical procedures. The company creates injectable and implantable products designed to support tissue repair and enhancement in cosmetic and reconstructive surgery.

BiotechHealthtechMedical DevicesNew Materials

Founders & leadership

MK
Milan KofolNamed on SEC filing
DS
Doug SheldonNamed on SEC filing
AH
Anh HoangNamed on SEC filing
HW
Howard WeismanNamed on SEC filing

Board

ANAmir Nashat
Amir NashatBoard directorEntrepreneur partner at Polaris Partners focused on healthcare investing and portfolio company executive roles

Investors · 2

Polaris PartnersinferredBoston · $500K – $5Mvia Amir Nashat · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$17.8M disclosed across 2 rounds · 2016–2019

▶$8.1MraisedSep 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Howard WeismanExecutive Officer, Director
  • Anh Hoang-LindsayDirector
  • S. Douglas SheldonDirector
Offering amount
$8.1M
Amount sold
$8.1M
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.7MraisedSep 2017 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Milan KofolExecutive Officer
  • Doug SheldonDirector
  • Anh HoangExecutive Officer
  • Howard WeismanExecutive Officer, Director
  • Amir NashatDirector
Offering amount
$9.7M
Amount sold
$9.7M
First sale
Sep 2016
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Sofregen went on to found or lead other companies.

Amir NashatDirectorFounded Jnana Therapeutics +3Jonathan HartmannChief Executive OfficerFounded Nirrin Technologies +1

In the news

Soft Tissue Engineering Biotechnology Company Sofregen Raises $8 Million in Series B Funding Roundprnewswire.com · Dec 2019Sofregen Medical Raises $6.2 Million in Series A Funding from Polaris Partners and Other Founding Investors — Sofregensofregen.com · Sep 2016

Frequently asked questions

What does Sofregen do?
Sofregen develops silk protein-based biomaterials and medical devices for soft tissue regeneration in aesthetic and surgical procedures. The company creates injectable and implantable products designed to support tissue repair and enhancement in cosmetic and reconstructive surgery.
Who are Sofregen's investors?
Sofregen's investors include Anzu Partners, Polaris Partners.
How much funding has Sofregen raised?
Sofregen has disclosed $17.8M raised across 2 rounds.
Where is Sofregen headquartered?
Sofregen is headquartered in Cambridge, US.